Clinical Trials Directory

Trials / Completed

CompletedNCT00151008

Bexarotene With Narrow-Band UVB for Psoriasis

Investigator-Initiated, Double Blind, Vehicle-Controlled, Bilateral Comparison Trial of Bexarotene (Targretin) Gel 1% vs. Vehicle Gel in Combination With Narrow Band UVB Phototherapy for Moderate to Severe Psoriasis Vulgaris

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
35 (planned)
Sponsor
University of Medicine and Dentistry of New Jersey · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

To determine if bexarotene gel with NBUVB phototherapy is more effective than placebo plus NBUVB for moderate to severe plaque-type psoriasis.

Detailed description

Subjects will be applying active gel or placebo to target lesions to each side of the body in a blinded manner. They will start at three times a week and increase to daily or even twice a day regimen if tolerated. After 2 weeks of application, NBUVB will be added to treatment regimen (whole body, three times a week). Total study time is 10 weeks.

Conditions

Interventions

TypeNameDescription
DRUGBexarotene/NBUVB vs placebo NBUVB

Timeline

Start date
2003-11-01
Completion
2005-08-01
First posted
2005-09-08
Last updated
2008-08-07

Source: ClinicalTrials.gov record NCT00151008. Inclusion in this directory is not an endorsement.

Bexarotene With Narrow-Band UVB for Psoriasis (NCT00151008) · Clinical Trials Directory